BAFNA PHARMACEUTICALS
|
BAFNA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 4.79 | 2.21 | 2.46 | -7.94 | -8.34 |
| CEPS(Rs) | 7.05 | 4.53 | 4.36 | 5.87 | -6.89 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 31.05 | 26.19 | 24.00 | -18.64 | 8.79 |
| Tax Rate(%) | 2.40 | - | - | - | -8.23 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.62 | 13.98 | 14.46 | 2.89 | -29.95 |
| EBIT Margin(%) | 11.84 | 7.06 | 9.22 | -4.20 | -36.91 |
| Pre Tax Margin(%) | 10.07 | 6.13 | 8.18 | -4.42 | -41.79 |
| PAT Margin (%) | 9.83 | 6.13 | 8.18 | -4.42 | -45.23 |
| Cash Profit Margin (%) | 14.45 | 12.58 | 14.47 | 3.27 | -37.38 |
| Performance Ratios | |||||
| ROA(%) | 10.32 | 5.91 | 7.40 | -1.96 | -15.90 |
| ROE(%) | 16.75 | 8.79 | 22.26 | -22.93 | -64.36 |
| ROCE(%) | 16.12 | 8.42 | 10.62 | -2.95 | -20.90 |
| Asset Turnover(x) | 1.05 | 0.96 | 0.90 | 0.44 | 0.35 |
| Sales/Fixed Asset(x) | 1.26 | 1.02 | 0.93 | 0.58 | 0.60 |
| Working Capital/Sales(x) | 2.82 | 2.95 | 2.81 | 2.26 | -1.95 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.79 | 0.98 | 1.08 | 1.73 | 1.67 |
| Receivable days | 88.49 | 52.17 | 39.96 | 132.64 | 205.45 |
| Inventory Days | 67.24 | 76.57 | 68.82 | 88.92 | 83.48 |
| Payable days | 118.26 | 105.56 | 133.55 | 586.42 | 512.64 |
| Valuation Parameters | |||||
| PER(x) | 17.24 | 57.59 | 55.74 | - | - |
| PCE(x) | 11.73 | 28.05 | 31.52 | 1.51 | -1.59 |
| Price/Book(x) | 2.66 | 4.85 | 5.72 | -0.48 | 1.25 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.83 | 3.66 | 4.72 | -0.08 | 1.59 |
| EV/Core EBITDA(x) | 11.09 | 22.79 | 30.42 | -2.27 | -5.47 |
| EV/EBIT(x) | 15.43 | 51.80 | 51.15 | 1.89 | -4.31 |
| EV/CE(x) | 1.63 | 3.45 | 3.89 | -0.05 | 0.58 |
| M Cap / Sales | 1.70 | 3.53 | 4.56 | 0.05 | 0.59 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 35.48 | 19.55 | 67.68 | -2.65 | -7.51 |
| Core EBITDA Growth(%) | 39.00 | 23.66 | 644.34 | 111.70 | -231.59 |
| EBIT Growth(%) | 127.17 | -8.50 | 468.50 | 88.93 | -115.56 |
| PAT Growth(%) | 117.34 | -10.47 | 410.26 | 90.48 | -19.94 |
| EPS Growth(%) | 117.34 | -10.47 | 131.03 | 4.82 | -19.94 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.31 | 0.18 | 0.23 | -0.68 | 2.22 |
| Current Ratio(x) | 1.88 | 2.31 | 2.04 | 2.10 | 0.68 |
| Quick Ratio(x) | 1.40 | 1.39 | 1.41 | 1.43 | 0.55 |
| Interest Cover(x) | 6.70 | 7.57 | 8.85 | -18.66 | -7.57 |
| Total Debt/Mcap(x) | 0.12 | 0.04 | 0.04 | 1.44 | 1.78 |
Compare Financial Ratios of peers of BAFNA PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BAFNA PHARMACEUTICALS | ₹236.4 Cr | -1.9% | 12.4% | 7.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹366,103.0 Cr | 0.7% | -4.8% | 57.3% | Stock Analytics | |
| CIPLA | ₹114,230.0 Cr | 1.9% | -2.4% | 42.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹103,916.0 Cr | 0.1% | 3% | 12.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹99,939.2 Cr | 1.3% | 0.5% | 87.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,732.2 Cr | -5.4% | -4.1% | 20% | Stock Analytics | |
BAFNA PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BAFNA PHARMACEUTICALS | -1.9% |
12.4% |
7.3% |
| SENSEX | -1.5% |
-2.6% |
17.8% |
You may also like the below Video Courses
